PHARMARON (03759) announced its financial results for the first three quarters of 2025. The group recorded operating revenue of RMB10.086 billion, representing a year-on-year increase of 14.38%. Net profit attributable to shareholders of the listed company stood at RMB1.141 billion, marking a 19.76% decline compared to the same period last year. Basic earnings per share were RMB0.6477.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.